Supply of OPV by M/s RITES Twenty Fourth Meeting Of the India Expert Advisory Group (IEAG) for Polio Eradication on 15 th March 2012 By S N Panda GM/Rites
Outline of Presentation Introduction Procurement Objective Supply overview Our Experience Recommendation
Introduction M/s RITES Limited(A PSU under Ministry of Rlys) assisting the Department of Health & Family Welfare as Procurement Agent for procurement of OPVs funded by External Agencies like World Bank since May’ 2010 previously handled by UNICEF In FY five indents were processed for four types of vaccines like bOPV, tOPV,mOPV1 and mOPV3 In FY two indents were processed for two types of vaccines like bOPV and tOPV only In FY one indent is already processed for bOPV (Supply in April – June 2012)
Vaccine Supply Objectives To ensure a sustained and uninterrupted supply of quality vaccines Through WHO Prequalification Appropriate contracting
Supply of OPV FYOPVIndent Qty (Million Doses) Procured Qty (Million Doses) Reasons for short procurement bOPV162100No offer /No responsive offer tOPV bOPV275 tOPV450109*No offer /No responsive offer/conditional offer bOPV340238No offer /No responsive offer for short notice supply bOPV300Procurement Plan under approval tOPV450 *One of the bidder’s manufacturing process was taken on review by WHO during decision process
Response From Suppliers in OPVNumber of prequalified Firms Number of Participated Firms Remarks bOPV63Only Indian suppliers participated tOPV63One foreign supplier participated
Installed Capacity of OPV Suppliers (Participated in RITES Tender) Firm NameInstalled Capacity Million Doses per annum M/s Panacea Biotec1600 M/s Haffkine600 M/s Sanofi Pasture4000 M/s Bharat Biotech1382
Our OPV Procurement Experience 50% of qualified suppliers participated in Bid Mostly suppliers from India participated though it was a LIB except M/s Sanofi from France No offer for full Bid quantity Appreciable gap in offered price of different suppliers
Reasons for low response Demand- Supply gap Shortage of bulk in International market Non participation of foreign suppliers due to (i) supply of OPV in short notice (ii) shelf life of minimum 18 months on the date of arrival at port of entry in India (iii) Marking of “CGS Not for Sale” on primary packaging
OPV Requirement for rounds OPVIndent Qty (Million Doses) Delivery Requirement Remarks bOPV5031/08/2012Procurement Plan Under Approval 10028/02/ /03/ /05/2013 Total300 tOPV22531/12/ /01/2013 Total450
Recommendation of RITES Indent should be sent at least 12 months in advance with respect to supply requirement so that tender can be finalised six months prior to requirements. This implies advanced planning and long term IEAG recommendations. Residual Shelf Life of vaccine at the time of supply as per Indian Drug & Cosmetic Act (i.e. 60% of total life of 24 months) instead of 18 months Waiver of “CGS Not for Sale” on primary packaging
Thank You